Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 6/20 | 0.50 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 12/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481417 | 0.85 | MAPK1 (0.56) | P4HTMMAPTKDM4EMAPK1L3MBTL1 | |
| SCHEMBL840870 | 0.74 | P4HTM (0.53) | P4HTMP4HA1MIFHCAR3MAPT | |
| SCHEMBL22060647 | 0.74 | P4HTM (0.66) | P4HTMP4HA1MIFHCAR3MAPT | |
| SCHEMBL211416 | 0.74 | P4HTM (0.66) | P4HTMP4HA1MIFHCAR3MAPT | |
| SCHEMBL14809913 | 0.74 | P4HTM (0.56) | P4HTMP4HA1MIFHCAR3MAPT | |
| SCHEMBL840867 | 0.74 | HCAR3 (0.59) | P4HTMP4HA1MIFHCAR3MAPT | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL70231 | 0.69 | P4HTM (1.00) | P4HTMP4HA1MIFHCAR3KDM4E | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL29363410 | 0.69 | P4HTM (1.00) | P4HTMP4HA1MIFHCAR3KDM4E | |
| SCHEMBL28630671 | 0.69 | P4HTM (0.58) | P4HTMP4HA1MIFHCAR3MAPT | |
| SCHEMBL7276744 | 0.68 | P4HA1 (0.61) | P4HTMP4HA1MIFHCAR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501451-B2 | Mono-acylated o-phenylendiamines derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7071219-B2 | Mono-acylated o-phenylendiamines derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060089403-A1 | Mono-acylated o-phenylendiamines derivatives | FERTIG GEORG | 2006-04-27 | — | — | US | disclosed |
| EP-1592667-A2 | NEW MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069803-A2 | MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES AND THEIR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089403-A1 | Mono-acylated o-phenylendiamines derivatives | HDAC1, HDAC10, HDAC11 | P4HTM 692/4885P4HA1 232/4885MIF 4459/4885 |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | HDAC1, HDAC11, HDAC10 | P4HTM 1825/4885P4HA1 343/4885MIF 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.